Illumina, Inc.
ILMNHealthcare · Medical - Diagnostics & Research · NASDAQ
$203.01
P/E 37.5×
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Investor model analysis
Details lockedIntrinsic Value (DCF)
Warren Buffett's valuation model · select an investor above to switch
Intrinsic Value
████
Buy Below
████
Strong Buy
████
Margin of Safety
████
Unlock buy targets with a free account
Get startedCreate a free account to see buy targets, full checklists & risk analysis Get started
Scenario analysis
Bear, base & bull
Three growth assumptions, three fair values — and where today's price lands
What's working
Key strengths
Identified by Buffett framework analysis
Company financials
5-Year Financials
Income statement highlights — annual, USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $4.3B | $4.4B | $4.5B | $4.6B | $4.5B |
| Rev. Growth | — | +0.8% | +3.0% | +1.8% | -1.3% |
| Net Income | $850M | -$1.2B | -$1.2B | -$4.4B | $762M |
| Net Margin | 19.6% | -28.0% | -25.8% | -96.1% | 16.8% |
| EPS (Diluted) | $5.48 | $-7.69 | $-7.35 | $-28.05 | $5.08 |
| Free Cash Flow | ████ | ████ | ████ | ████ | ████ |
Full analysis included
See the complete picture for ILMN
Exact buy targets, margin of safety, detailed investor checklists, and risk breakdown — all frameworks, all numbers.
Free: 3 analyses/month · Pay per stock: $4.99 · Pro: $19.99/mo
Educational Use Only · Not Financial Advice
Analysis, scores, valuations, and buy zones are derived from publicly documented investor frameworks (Buffett, Lynch, Benjamin Graham, Phil Town) for learning purposes only. They are not recommendations from licensed financial advisors. Past performance does not guarantee future results. Prices may be delayed up to 15 minutes. Always conduct your own research before making any investment decisions.